Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (2024)

Table of Contents
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update Genprex to Present at the 2024 BIO International Convention Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner Genprex to Present and Participate at Upcoming May Investor and Industry Conferences Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators Genprex to Present at Upcoming BIO CEO & Investor Conference Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 Genprex Provides Business Update and Outlook for 2024 Genprex to Present at BIO-Europe 2023 Conference Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers" Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC Genprex to Present at Upcoming September Investor Conference Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer FAQs

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (1)

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex...

26 days ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (2)

Genprex to Present at the 2024 BIO International Convention

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...

7 weeks ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (3)

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas , May 14, 2024 /PRNewswire/ -- Genprex...

2 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (4)

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNewswire/ --Genprex, Inc. ("Genprex" or the "Company") (NASDAQ...

2 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (5)

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc.("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage g...

2 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (6)

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients...

2 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (8)

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Design...

3 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (9)

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validation of Oncoprex® Del...

4 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (10)

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc.("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...

4 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (11)

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc.("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...

4 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (12)

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas , M...

4 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (13)

See Also
Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells NPRL2 Gene Therapy Induces ...

4 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (14)

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Reqorsa®Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association ...

5 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (15)

Genprex to Present at Upcoming BIO CEO & Investor Conference

Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene...

6 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (16)

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Acclaim-1 Study Has FDA Fast Track Designation AUSTIN, Texas , Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc.("Genprex" or th...

6 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (17)

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...

6 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (18)

Genprex Provides Business Update and Outlook for 2024

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , Jan. 5, 2024 /P...

7 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (19)

Genprex to Present at BIO-Europe 2023 Conference

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...

9 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (20)

Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"

Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time AUSTIN, Texas , Oct. 20, 2023 /PRNewswire/ --Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-...

9 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (21)

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical res...

10 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (22)

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brand...

10 months ago - GlobeNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (23)

Genprex to Present at Upcoming September Investor Conference

Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 7, 2023 /PRNewswire/ --Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gen...

11 months ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (24)

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer ...

1 year ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (25)

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the­­­­ Acclaim-3 clinical trial in the fourth quarter of 2023 AUSTIN, Texas , Aug. 10, 2023 /PRNe...

1 year ago - PRNewsWire

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis? ›

Analysts like Genprex more than other "medical" companies. The consensus rating for Genprex is Buy while the average consensus rating for "medical" companies is Moderate Buy.

Tell Me More ›
Is Genprex a good stock to buy? ›

Analysts like Genprex more than other "medical" companies. The consensus rating for Genprex is Buy while the average consensus rating for "medical" companies is Moderate Buy.

View Details ›
What is the price prediction for Genprex? ›

The average one-year price target for Genprex, Inc. is $168.30. The forecasts range from a low of $10.10 to a high of $336.00. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

See More ›
What is the hottest stock to invest in? ›

The 9 Best Stocks To Buy Now
Company (Ticker)Forward P/E Ratio
Spotify Technology S.A. (SPOT)20.9
The Progressive Corporation (PGR)8.6
Alphabet, Inc. (GOOG, GOOGL)13.2
Intuitive Surgical, Inc. (ISRG)52.2
5 more rows
Jul 1, 2024

Find Out More ›
What is the stock forecast for GNPX in 2030? ›

Genprex Stock Prediction 2030

In 2030, the Genprex stock will reach $ 255.08 if it maintains its current 10-year average growth rate. If this Genprex stock prediction for 2030 materializes, GNPX stock will grow 12,718.02% from its current price.

See Details ›
What is the price prediction for bancor in 2030? ›

Bancor (BNT) Price Prediction 2030
YearPrice
2025$ 0.666853
2026$ 0.700196
2027$ 0.735206
2030$ 0.851093
1 more row

Find Out More ›
What is the price prediction for ADTX 2025? ›

$62.22 ↑2,665.21% Estimated share price by May 22, 2025.

Keep Reading ›
What is the price prediction for MLN in 2025? ›

Enzyme (MLN) Price Prediction 2030
YearPrice
2024$ 19.44
2025$ 20.41
2026$ 21.43
2027$ 22.51
1 more row

View Details ›
What is the target price for Neogen stock? ›

Stock Price Targets
High$17.00
Median$17.00
Low$17.00
Average$17.00
Current Price$16.45

View More ›
What is the target price for eh stock? ›

The average price target for Ehang Holdings is $21.75. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $27.50 ,the lowest forecast is $16.00. The average price target represents 59.11% Increase from the current price of $13.67.

Get More Info Here ›

What is the future of RH stock? ›

RH Stock 12 Month Forecast

Based on 14 Wall Street analysts offering 12 month price targets for RH in the last 3 months. The average price target is $292.17 with a high forecast of $350.00 and a low forecast of $226.00.

See More ›
What is the target price for Blph stock? ›

Stock Price Target BLPH
High$19.00
Median$19.00
Low$19.00
Average$19.00
Current Price$0.05

Keep Reading ›
Top Articles
Brotherhood Recon Jet Pack
Used Harley-Davidson® Motorcycles For Sale in The USA
Food King El Paso Ads
Craigslist Vans
Chase Bank Operating Hours
Craigslist - Pets for Sale or Adoption in Zeeland, MI
Here's how eating according to your blood type could help you keep healthy
Shaniki Hernandez Cam
Bubbles Hair Salon Woodbridge Va
Does Pappadeaux Pay Weekly
Oxford House Peoria Il
Caliber Collision Burnsville
charleston cars & trucks - by owner - craigslist
5 high school volleyball stars of the week: Sept. 17 edition
Walmart Double Point Days 2022
Rams vs. Lions highlights: Detroit defeats Los Angeles 26-20 in overtime thriller
Everything We Know About Gladiator 2
Earl David Worden Military Service
Full Standard Operating Guideline Manual | Springfield, MO
Geometry Review Quiz 5 Answer Key
Forest Biome
Beverage Lyons Funeral Home Obituaries
Heart Ring Worth Aj
Touchless Car Wash Schaumburg
At 25 Years, Understanding The Longevity Of Craigslist
Nail Salon Open On Monday Near Me
P3P Orthrus With Dodge Slash
Beth Moore 2023
PA lawmakers push to restore Medicaid dental benefits for adults
Domina Scarlett Ct
ATM Near Me | Find The Nearest ATM Location | ATM Locator NL
Craigslist Pets Huntsville Alabama
National Insider Threat Awareness Month - 2024 DCSA Conference For Insider Threat Virtual Registration Still Available
Review: T-Mobile's Unlimited 4G voor Thuis | Consumentenbond
20 bank M&A deals with the largest target asset volume in 2023
Academy Sports New Bern Nc Coupons
Gopher Hockey Forum
Jamesbonchai
Lady Nagant Funko Pop
Oklahoma City Farm & Garden Craigslist
Dontrell Nelson - 2016 - Football - University of Memphis Athletics
What is a lifetime maximum benefit? | healthinsurance.org
John Wick: Kapitel 4 (2023)
2294141287
Gonzalo Lira Net Worth
Kenwood M-918DAB-H Heim-Audio-Mikrosystem DAB, DAB+, FM 10 W Bluetooth von expert Technomarkt
Fine Taladorian Cheese Platter
Jeep Forum Cj
Heat Wave and Summer Temperature Data for Oklahoma City, Oklahoma
Msatlantathickdream
Www Ventusky
Factorio Green Circuit Setup
Latest Posts
Used Cruisers Yachts 42' 42 GLS For Sale In Florida | CELEBRATE | United Yacht Sales
Cruisers Yachts 42GLS - EASY FINANCING - SAME DAY APPROVAL 2021 for sale for $1,793
Article information

Author: Horacio Brakus JD

Last Updated:

Views: 5327

Rating: 4 / 5 (51 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Horacio Brakus JD

Birthday: 1999-08-21

Address: Apt. 524 43384 Minnie Prairie, South Edda, MA 62804

Phone: +5931039998219

Job: Sales Strategist

Hobby: Sculling, Kitesurfing, Orienteering, Painting, Computer programming, Creative writing, Scuba diving

Introduction: My name is Horacio Brakus JD, I am a lively, splendid, jolly, vivacious, vast, cheerful, agreeable person who loves writing and wants to share my knowledge and understanding with you.